Expression of peroxisome proliferator‐activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists

Abstract

Recent studies have demonstrated that peroxisome proliferator activator‐receptors(PPAR)‐γ is expressed in various cancer tissues and its ligand induces growth arrest of these cancer cells through apoptosis. In our study, we investigated the expression of PPAR‐α, β and γ in human bladder tumor (BT) and normal bladder (NB) tissues as well as the effects of PPAR‐γ ligands. Specimens were obtained from 170 patients with BT and 20 with NB. The expressions were investigated using RT‐PCR and immunohistochemical methods. We also investigated the inhibitory effect of PPAR‐γ ligands on BT‐derived cell line. Immunoreactive PPAR‐α and ‐β were significantly apparent in both BT and NB tissues. Although no marked expression of PPAR‐γ was observed in NB tissue, significant expression was found in BT tissue. The extent and intensity of immunoreactive PPAR‐γ polypeptides in BT cells were statistically much greater than those of NB cells. Correlation between PPAR‐γ expression and tissue type or progression of bladder cancer was observed; PPAR‐γ expression was higher in G3 of bladder cancer than in G1 and was higher in advanced than in early cancer. PPAR‐γ agonists, troglitazone and 15‐deoxy‐Δ^{12, 14}‐prostaglandin J₂ inhibited the growth of the BT cells. PPAR‐γ is expressed in bladder tumor, and results suggest that PPAR‐γ ligands may mediate potent antiproliferative effects against BT cells. Thus, PPAR‐γ has the ability to become a new target in treatment of bladder tumor.